

WO 00/26350

What is claimed is:

5

10

20

25

35

- 1. A substantially purified polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-5 and fragments thereof.
- 2. A substantially purified variant having at least 90% amino acid sequence identity to the amino acid sequence of claim 1.
 - 3. An isolated and purified polynucleotide encoding the polypeptide of claim 1.
- 4. An isolated and purified polynucleotide variant having at least 70% polynucleotide sequence identity to the polynucleotide of claim 3.
- 5. An isolated and purified polynucleotide which hybridizes under stringent conditions to the polynucleotide of claim 3.
 - 6. An isolated and purified polynucleotide having a sequence which is complementary to the polynucleotide of claim 3.
 - 7. A method for detecting a polynucleotide, the method comprising the steps of:
 - (a) hybridizing the follynucleotide of claim 6 to at least one nucleic acid in a sample, thereby forming a hybridization complex; and
 - (b) detecting the hybridization complex, wherein the presence of the hybridization complex correlates with the presence of the polynucleotide in the sample.
 - 8. The method of claim 7 further comprising amplifying the polynucleotide prior to hybridization.
- 9. An isolated and purified polynucleotide comprising a polynucleotide sequence 30 selected from the group consisting of SEQ ID NO:6-10 and fragments thereof.
 - 10. An isolated and purified polynucleotide variant having at least 70% polynucleotide sequence identity to the polynucleotide of claim 9.
 - 11. An isolated and purified polynucleotide having a sequence which is complementary



WO 00/26350 PCT/US99/25820

to the polynucleotide of claim 9.

10

15

20

- 12. An expression vector comprising at least a fragment of the polynucleotide of claim 3.
- 5 13. A host cell comprising the expression vector of claim 12.
 - 14. A method for producing a polypeptide, the method comprising the steps of:
 - a) culturing the host cell of claim 13 under conditions suitable for the expression of the polypeptide; and
 - b) recovering the polypeptide from the host cell culture.
 - 15. A pharmaceutical composition comprising the polypeptide of claim 1 in conjunction with a suitable pharmaceutical carrier.
 - 16. A purified antibody which specifically binds to the polypeptide of claim 1.
 - 17. A purified agonist of the polypeptide of claim 1.
 - 18. A purified antagonist of the polypeptide of claim 1.
 - 19. A method for treating or preventing a disorder associated with decreased expression or activity of CoAEN, the method comprising administering to a subject in need of such treatment an effective amount of the pharmaceutical composition of claim 15.
- 25 20. A method for treating or preventing a disorder associated with increased expression or activity of CoAEN, the method comprising administering to a subject in need of such treatment an effective amount of the antagonist of claim 18.